{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:28:30Z","timestamp":1790180910875,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Bec2 is an anti-idiotypic antibody that mimics GD3, a ganglioside that is expressed on the surface of tumor cells and is of neuroectodermal origin. We assessed whether Bec2\/bacille Calmette-Guerin (BCG) vaccination prolongs survival in patients with limited-disease small-cell lung cancer (SCLC) after a major response to chemotherapy and chest radiation. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients were randomly assigned to receive five vaccinations of Bec2 (2.5 mg)\/BCG vaccine or follow-up. Vaccination was given over a 10-week period. The sample size was targeted to detect an increase in median survival of 40% after random assignment, and stratification was by performance status, response, and institution. Quality of life was assessed by using the European Organisation for Research and Treatment of Cancer instrument. Humoral response was assessed in patients who received vaccination. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> A total of 515 patients were randomly assigned. The primary toxicities of vaccination were transient skin ulcerations and mild flu-like symptoms. There was no improvement in survival, progression-free survival, or quality of life in the vaccination arm. Median survival from randomization was 16.4 and 14.3 months in the observation and vaccination arms (P = .28), respectively. Among vaccinated patients, a trend toward prolonged survival was observed in those (one third) who developed a humoral response (P = .085). Multivariate analysis showed a positive impact on survival by prior treatment with concomitant chemoradiotherapy, prophylactic cranial irradiation, female sex, low lactate dehydrogenase, and normal platelets. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Vaccination with Bec2\/BCG has no impact on outcome of patients with limited-disease SCLC responding to combined-modality treatment. Vaccination strategies in SCLC may still be warranted using vaccines that produce a better immunologic response. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.17.186","type":"journal-article","created":{"date-parts":[[2005,9,28]],"date-time":"2005-09-28T19:18:42Z","timestamp":1127935122000},"page":"6854-6864","source":"Crossref","is-referenced-by-count":164,"title":["Phase III Study of Adjuvant Vaccination With Bec2\/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)"],"prefix":"10.1200","volume":"23","author":[{"given":"Giuseppe","family":"Giaccone","sequence":"first","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channa","family":"Debruyne","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Chapman","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan C.","family":"Grant","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Thiberville","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannicola","family":"D'addario","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneel","family":"Coens","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa S.","family":"Rome","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Zatloukal","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Masso","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Legrand","sequence":"additional","affiliation":[{"name":"From the Vrije Universiteit Medical Center, Amsterdam, the Netherlands (on behalf of the EORTC Lung Cancer Group); EORTC Data Center, Brussels, Belgium (C. Coens, on behalf of the EORTC Quality of Life Unit); Vall d'Hebron University Hospital, Barcelona, Spain (on behalf of the Spanish Lung Cancer Group); Memorial Sloan-Kettering Cancer Center, New York, NY; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, Australia (on behalf of centers in Australia and New Zealand); Clinique..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.1.10"},{"key":"R2","unstructured":"Krug LM, Grant SC, Miller VA, et al: Strategies to eradicate minimal residual disease in small cell lung cancer: High-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination. Semin Oncol 26:55,1999-61,  (5 suppl 15)"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(86)90244-4"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(99)00107-5"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Fuentes R, Allman R, Mason MD: Ganglioside expression in lung cancer cell lines. Lung Cancer 18:21,1997-33,","DOI":"10.1016\/S0169-5002(97)00049-4"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910620604"},{"key":"R8","unstructured":"McCaffery M, Yao TJ, Williams L, et al: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 2:679,1996-686,"},{"key":"R9","unstructured":"Yao TJ, Meyers M, Livingston PO, et al: Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 5:77,1999-81,"},{"key":"R10","unstructured":"Grant SC, Kris MG, Houghton AN, et al: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 5:1319,1999-1323,"},{"key":"R11","unstructured":"Chapman PB: Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs 4:710,2003-715,"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0345"},{"key":"R13","unstructured":"Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 4:31,1973-42,"},{"key":"R14","unstructured":"Klimek VM, Williams LJ, Holland S, et al: Bacillus Calmette-Guerin (BCG) can be used safely as an immunological adjuvant in patients with a positive PPD or a history of tuberculosis (TB). Proc Am Soc Clin Oncol 19:466a,2000,  (abstract)"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.12.028"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-003-0032-9"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400403"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1230"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.118"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2337"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2114"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.12.1864"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3531"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1997.17.103"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Mattson K, Niiranen A, Pyrhonen S, et al: Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 28A:1387,1992-1391,","DOI":"10.1016\/0959-8049(92)90526-8"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1089\/107999099314180"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2924"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00174-3"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2321"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.22.1844"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.108"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.106.1.287"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861201)58:11<2411::AID-CNCR2820581110>3.0.CO;2-C"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1007\/BF00199131"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212033272302"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908123410703"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1007\/PL00014042"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.19.3976"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1007\/BF01731837"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.3549"},{"key":"R41","unstructured":"Ragupathi G, Livingston PO, Hood C, et al: Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 9:5214,2003-5220,"},{"key":"R42","unstructured":"Niculescu-Duvaz I: Technology evaluation: EMD-273063, EMD Lexigen. Curr Opin Mol Ther 6:559,2004-566,"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.035"},{"key":"R44","unstructured":"Dickler MN, Ragupathi G, Liu NX, et al: Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 5:2773,1999-2779,"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0482"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(03)00153-3"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.17.186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:38:29Z","timestamp":1653496709000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.17.186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":46,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2005,10,1]]}},"alternative-id":["10.1200\/JCO.2005.17.186"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.17.186","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,1]]}}}